I lead Research and Development in Oncology at AstraZeneca and am responsible for discovery through late-stage development of large and small molecules.

Prior to my role at AstraZeneca, I served as the Physician-in-Chief and Chief Medical Officer at Memorial Sloan Kettering Cancer Center (MSK) and Professor of Medicine at Weill Cornell Medical College. In this capacity, I had nearly 2,000 physicians reporting to me and under my leadership, MSK became the leader in early phase clinical trials for cancer therapies and diagnostic genetic sequencing.

My long-standing research interests are in the development of targeted agents for the treatment of cancer and in studying strategies to overcome mechanisms of resistance. My passion for drug development has also led to the creation of a number biopharmaceutical companies.

Prior to joining MSKCC, I was Chief of the Division of Hematology/Oncology and Associate Director at the Massachusetts General Hospital Cancer Center and Professor of Medicine at Harvard Medical School. I was also the Chairman of Medical Oncology and Founding Director of the Vall d ‘Hebron Institute of Oncology in Barcelona, Spain.


The possibilities of scientific discovery are endless, but it is up to us as researchers and innovators to bring them forward to improve the lives of patients.

José Baselga Executive Vice-President, Research & Development Oncology
金沙官网

金沙官网8331澳门

金沙官网8331澳门

金沙集团

金沙官网8331澳门

金沙官网8331澳门

金沙正规投注官网

金沙官网8331澳门

金沙官网8331澳门


金沙官网登录注册

Key Achievements

金沙网站

2019

金沙网站

2000 - 2015

金沙网站

2014

金沙网站

金沙网站

Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer.金沙官网8331澳门

Baselga J, Campone M, Piccart M, Burris HA, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck JT, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu Z, Mukhopadhyay P, Lebwohl D, Hortobagyi GN. N Engl J Med. 2012; 366:520-9.

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.金沙官网8331澳门

von Minckwitz G*, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, Suter T, Arahmani A, Rouchet N, Clark E, Knott A, Lang I, Levy C, Yardley DA, Bines J, Gelber RD, Piccart M, Baselga J*; APHINITY Steering Committee and Investigators. N Engl J Med. 2017 Jun 5; 377:122-131.  PMCID:PMC5538020.  *Co-corresponding authors. 

Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study.金沙官网8331澳门

Juric D, Rodon J, Tabernero J, Janku F, Burris HA, Schellens JHM, Middleton MR, Berlin J, Schuler M, Gil-Martin M, Rugo HS, Seggewiss-Bernhardt R, Huang A, Bootle D, Demanse D, Blumenstein L, Coughlin C, Quadt C, Baselga J. J Clin Oncol. 2018 May 1;36(13):1291-1299.

Convergent loss of PTEN leads to clinical resistance to a PI3Kα inhibitor.金沙官网8331澳门

Juric D, Castel P, Griffit M, Griffith OL, Won HH, Ellis H, Ebbesen S, Ainscough BJ, Ramu A, Iyer G, Shah RH, Huynh T, Mino-Kenudson M, Sgroi D, Isakoff S, Thabet A, Elamine L, Solit DB, Lowe SW, Quadt C, Peters M, Derti A, Schegel R, Huang A, Mardis ER, Berger MF, Baselga J*, Scaltriti M. Nature. 2015 Feb 12; 518(7538):240-4

PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D.金沙官网8331澳门

Toska E, Osmanbeyoglu HU, Castel P, Chan C, Hendrickson RC, Elkabets M, Dickler MN, Scaltriti M, Leslie CS, Armstrong SA, Baselga J.
Science. 2017 Mar 24;355(6331):1324-1330.

The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers.金沙官网8331澳门

Razavi P, Chang MT, Xu G, Bandlamudi C, Ross DS, Vasan N, Cai Y, Bielski CM, Donoghue MTA, Jonsson P, Penson A, Shen R, Pareja F, Kundra R, Middha S, Cheng ML, Zehir A, Kandoth C, Patel R, Huberman K, Smyth LM, Jhaveri K, Modi S, Traina TA, Dang C, Zhang W, Weigelt B, Li BT, Ladanyi M, Hyman DM, Schultz N, Robson ME, Hudis C, Brogi E, Viale A, Norton L, Dickler MN, Berger MF, Iacobuzio-Donahue CA, Chandarlapaty S, Scaltriti M, Reis-Filho JS, Solit DB, Taylor BS & Baselga J (2018). Cancer Cell 34, 427-438 e426.